| abstract |
The novel pyrazolobenzodiazepines of formula (I) and their pharmaceutically acceptable salts, wherein R 1 , R 2 , R 3 and R 4 are as defined herein, are characterized as cyclin dependent kinases (CDK), in particular CDK2. It is an antiproliferative agent which inhibits and is useful for the treatment or control of cell proliferative disorders, especially breast cancer, colon cancer, lung cancer and prostate cancer. |